Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments

Tthe EuOrphan Service

Donatas Stakišaitis, Indrė Špokienė, Jonas Juškevičius, Konstantinas Povilas Valuckas, Paola Baiardi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalMedicina
Volume43
Issue number6
Publication statusPublished - 2007

Fingerprint

Access to Information
Rare Diseases
Therapeutics
Delivery of Health Care
Orphaned Children
Quality of Health Care
Drug Industry
Legislation
Pharmaceutical Preparations
Health Personnel
Public Health
Research Personnel
Clinical Trials
Organizations
Physicians
Population

Keywords

  • Rare disease
  • Orphan drugs

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments : Tthe EuOrphan Service. / Stakišaitis, Donatas ; Špokienė, Indrė; Juškevičius, Jonas; Valuckas, Konstantinas Povilas; Baiardi, Paola.

In: Medicina, Vol. 43, No. 6, 2007, p. 441-446.

Research output: Contribution to journalArticle

@article{0c2b07e5a6b94eaea21d2832cda48b1e,
title = "Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: Tthe EuOrphan Service",
abstract = "Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.",
keywords = "Rare disease, Orphan drugs",
author = "Donatas Stakišaitis and Indrė Špokienė and Jonas Juškevičius and Valuckas, {Konstantinas Povilas} and Paola Baiardi",
year = "2007",
language = "English",
volume = "43",
pages = "441--446",
journal = "Medicina",
issn = "1010-660X",
publisher = "Kauno Medicinos Universitetas",
number = "6",

}

TY - JOUR

T1 - Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments

T2 - Tthe EuOrphan Service

AU - Stakišaitis, Donatas

AU - Špokienė, Indrė

AU - Juškevičius, Jonas

AU - Valuckas, Konstantinas Povilas

AU - Baiardi, Paola

PY - 2007

Y1 - 2007

N2 - Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

AB - Currently in Europe, approximately 30 million people suffer from rare diseases, and a major problem is that many patients do not have access to quality healthcare for their disorders. Moreover, there is also a lack of quality information and a networking system aimed at supporting interaction among patients, clinicians, researchers, pharmaceutical industries, and governmental bodies. The purpose of this article is to inform physicians, public health care professionals, and other health care providers about EuOrphan service, the aim of which is to ensure easier access to quality information on rare diseases and their treatment. A set of web-based services is available at www.euorphan.com where information for target-users on treatments and products available worldwide for rare disease care as well as indications about healthcare centers are provided. Moreover, the service aims at providing consultancies for pharmaceutical companies to ultimately support the European legislation in bringing new drugs of a high ethical standard to the market and to exert a positive impact on the large population of patients suffering from rare diseases in Europe. The services provided by EuOrphan can facilitate concrete networking among patients, patient associations, doctors, and companies and also support the organization of clinical trials. In this perspective, EuOrphan could become a very valuable tool for globalizing the information about the availability of treatment (authorized or under development) of orphan patients.

KW - Rare disease

KW - Orphan drugs

UR - http://www.scopus.com/inward/record.url?scp=34748880066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748880066&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 441

EP - 446

JO - Medicina

JF - Medicina

SN - 1010-660X

IS - 6

ER -